Abstract: Objective  To evaluate the efficacy and safety of desloratadine in the patients with chronic urticarial (cu). Methods  WanFang Data,  CNKI, VIP,  Cochrane Library，PubMed，Medline and EMbase database from January,  2000 to June,  2018were searched  to collect casecontrol studies about the association between desloratadine and other antihistamine medicine. Relevant journals and conference proceedings were also manuallysearched. Two reviewers independently screened literature,  evaluated quality,  extracted data and assessed the risk of bias of included studies. Then,  Metaanalysis was conducted using RevMan 5.0 software. Results  A total of 47 trials involving 4 972 participants contributed to the meta analysis. The results of the metaanalysis indicated that desloratadine showed better effect on the improvement of signs and symptoms compared with other antihistamine medicine(RR=1.06，95%CI=1.03~1.09，P=0.0003). Further subgroup analysis showed that efficacy of dicloretadine is inspecially better than chloretadine（RR=1.05，95%CI=1.001.10，P=0.04）,  mizuositing（RR=1.10，95%CI=1.031.16，P=0.002）  and siltiriazine（RR=1.07，95%CI=1.021.13，P=0.008）. At the same time,  desloratadine was safer than other antihistamine medicine(OR=0.73，95%CI=0.600.90，P=0.003). Conclusion  Desloratadine has  more advantages in the treatment of chronic urticaria,  and the safety is relatively reliable. It is an efficient and longlasting drug. which makes it very suitable for extensive clinical application.

Key words: desloratadine, antihistamine medicine, urticaria; , metaanalysis